Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: Feasibility assessment for future mass spectrometry …
Despite the popularity of targeted and immune therapies, the number of studies dealing with
the quantitation of aggregates for Food and Drug Administration (FDA) and European …
the quantitation of aggregates for Food and Drug Administration (FDA) and European …
Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: Feasibility assessment for future mass spectrometry …
A Goyon, V D'Atri, O Colas, S Fekete, A Beck… - … of chromatography. B …, 2017 - sonar.ch
English Despite the popularity of targeted and immune therapies, the number of studies
dealing with the quantitation of aggregates for Food and Drug Administration (FDA) and …
dealing with the quantitation of aggregates for Food and Drug Administration (FDA) and …
Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: Feasibility assessment for future mass spectrometry …
A Goyon, V D'Atri, O Colas, S Fekete… - … of chromatography. B …, 2017 - europepmc.org
Despite the popularity of targeted and immune therapies, the number of studies dealing with
the quantitation of aggregates for Food and Drug Administration (FDA) and European …
the quantitation of aggregates for Food and Drug Administration (FDA) and European …
[引用][C] Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: Feasibility assessment for future mass spectrometry …
A Goyon, V D'Atri, O Colas, S Fekete, A Beck… - … of Chromatography B, 2017 - cir.nii.ac.jp
Characterization of 30 therapeutic antibodies and related products by size exclusion
chromatography: Feasibility assessment for future mass spectrometry hyphenation | CiNii …
chromatography: Feasibility assessment for future mass spectrometry hyphenation | CiNii …
Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: Feasibility assessment for future mass spectrometry …
A Goyon, V D'Atri, O Colas, S Fekete, A Beck… - … of chromatography. B …, 2017 - folia.unifr.ch
English Despite the popularity of targeted and immune therapies, the number of studies
dealing with the quantitation of aggregates for Food and Drug Administration (FDA) and …
dealing with the quantitation of aggregates for Food and Drug Administration (FDA) and …
Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: Feasibility assessment for future mass spectrometry …
A Goyon, V D'Atri, O Colas, S Fekete… - … technologies in the …, 2017 - pubmed.ncbi.nlm.nih.gov
Despite the popularity of targeted and immune therapies, the number of studies dealing with
the quantitation of aggregates for Food and Drug Administration (FDA) and European …
the quantitation of aggregates for Food and Drug Administration (FDA) and European …